| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS |
95%
|
USAspending awards from Department of Veterans Affairs: $203,367 across 10 awards. 36C25725K0072 EXPRESS REPORT: INVACARE TDX SP2 BASE FOR MULTIPLE ACTUATOR SYSTEM; 36C26225P0281 PROSTHETICS:IMPLANT… |
| HOSPITALS |
HOSPITALS |
90%
|
The Company earns revenue primarily from the sale of its products to hospitals and other customers such as distributors. |
| CM |
Canadian Imperial Bank of Commerce |
72%
|
fied in the Perceptive Agreement. The occurrence of an event of default under the Perceptive Agreement could result in, among other things, the declaration that all outstanding principal and interest… |
| CM |
Canadian Imperial Bank of Commerce |
72%
|
Reciprocal relationship from CM graph: Reciprocal relationship from LUNG graph: Reciprocal relationship from CM graph: Reciprocal relationship from LUNG graph: fied in the Perceptive Agreement. The o… |
| ANTHEM-HEALTH-CARE-SERVICE-CORPORATION |
ANTHEM-HEALTH-CARE-SERVICE-CORPORATION |
62%
|
ial condition and results of operations. Moreover, perceptions regarding the safety of the Zephyr Valve could be affected even if such complications are unrelated to the Zephyr Valve or treatment wit… |
| BRONCUS-MEDICAL-INC |
BRONCUS-MEDICAL-INC |
62%
|
non-coverage policy exists. We expect that continued patient demand coupled with successful appeals of any initially denied prior authorization requests will lead to more positive coverage policies. … |
| CONTROL-GROUP |
CONTROL-GROUP |
62%
|
alternatives; and • introduction of other novel alternative therapies to treat severe emphysema. We focus our sales, marketing and training efforts primarily on pulmonologists. However, physicians fr… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
cable deadlines, failure to apply before expiration of relevant patents, or some other failure to satisfy applicable requirements. If this occurs, our competitors may be able to launch their products… |
| DEPOSIT-INSURANCE-CORPORATION |
DEPOSIT-INSURANCE-CORPORATION |
62%
|
ral Deposit Insurance Corporation (“FDIC”) insured limits. As of March 31, 2026 and December 31, 2025, the Company also had cash on deposit with foreign banks of approximately $ 10.1 million and $ 13… |
| F-12-PULMONX-CORPORATION |
F-12-PULMONX-CORPORATION |
62%
|
tion price adjustments. The Company’s payment terms to customers generally range from 30 to 60 days. F-12 Pulmonx Corporation Notes to Consolidated Financial Statements Payment terms fall within the … |
| F-13-PULMONX-CORPORATION |
F-13-PULMONX-CORPORATION |
62%
|
ither upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. For consignment sales, control is transferred when the products are used by the custom… |
| F-14-PULMONX-CORPORATION |
F-14-PULMONX-CORPORATION |
62%
|
ither upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. For consignment sales, control is transferred when the products are used by the custom… |
| F-15-PULMONX-CORPORATION |
F-15-PULMONX-CORPORATION |
62%
|
gregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses , which requires disclosure in the notes to the financial statements of specified information about certain costs … |
| F-18-PULMONX-CORPORATION |
F-18-PULMONX-CORPORATION |
62%
|
s $ 69,751 $ 70,905 F-18 Pulmonx Corporation Notes to Consolidated Financial Statements Inventory Inventory consists of the following (in thousands): December 31, 2025 2024 Raw materials $ 4,872 $ 3,… |
| F-19-PULMONX-CORPORATION |
F-19-PULMONX-CORPORATION |
62%
|
s $ 69,751 $ 70,905 F-18 Pulmonx Corporation Notes to Consolidated Financial Statements Inventory Inventory consists of the following (in thousands): December 31, 2025 2024 Raw materials $ 4,872 $ 3,… |
| F-9-PULMONX-CORPORATION |
F-9-PULMONX-CORPORATION |
62%
|
and accounts receivable. The Company maintains its cash and cash equivalents balances with established F-9 Pulmonx Corporation Notes to Consolidated Financial Statements financial institutions and, a… |
| FEDERAL-F-9-PULMONX-CORPORATION |
FEDERAL-F-9-PULMONX-CORPORATION |
62%
|
cess of the Federal F-9 Pulmonx Corporation Notes to Consolidated Financial Statements Deposit Insurance Corporation (“FDIC”) insured limits. As of December 31, 2025 and December 31, 2024, the Compan… |
| HUMAN-CAPITAL-MANAGEMENT-EMPLOYEES-TALENT-MANAGE |
HUMAN-CAPITAL-MANAGEMENT-EMPLOYEES-TALENT-MANAGE |
62%
|
tory damages. In addition, the California Privacy Rights Act of 2020 (“CPRA”), which became effective January 1, 2023, expands the CCPA by, among other things, giving California residents the ability… |
| MEDICAL-DEVICES-COORDINATION-GROUP |
MEDICAL-DEVICES-COORDINATION-GROUP |
62%
|
application, as a condition of approval, the FDA may also require some form of post-approval study (“PAS”) or post-market surveillance, whereby the applicant conducts a follow-up study or follows cer… |
| MICHIGAN-HUMANA-HEALTH-CARE-SERVICE-CORPORATION |
MICHIGAN-HUMANA-HEALTH-CARE-SERVICE-CORPORATION |
62%
|
e no assurance that our solution will gain a substantial degree of market acceptance among specialty physicians, patients or healthcare providers. Our failure to successfully increase sales of our so… |
| OLYMPUS-MEDICAL-SYSTEMS-CORP |
OLYMPUS-MEDICAL-SYSTEMS-CORP |
62%
|
orm, and future product concepts. The term of individual patents depends on the legal term for patents in the countries in which they are granted. In most countries, including the United States, the … |
| PERCEPTIVE-CREDIT-HOLDINGS |
PERCEPTIVE-CREDIT-HOLDINGS |
62%
|
and raw materials, may be the basis for a claim against us. Product liability claims may be brought against us by patients, physicians, or others selling or otherwise coming into contact with the Zep… |
| ZEPHYR-VALVE-GROUP |
ZEPHYR-VALVE-GROUP |
62%
|
alternatives; and • introduction of other novel alternative therapies to treat severe emphysema. We focus our sales, marketing and training efforts primarily on pulmonologists. However, physicians fr… |
